Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Neurology. 2023 Apr 4;100(14):688. doi: 10.1212/WNL.0000000000207210.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antigens, CD19
  • Cell- and Tissue-Based Therapy
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Lymphoma, B-Cell* / therapy
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen* / therapeutic use

Substances

  • Receptors, Chimeric Antigen
  • Antigens, CD19
  • Receptors, Antigen, T-Cell